Business Wire

GWI

9.9.2021 06:03:06 CEST | Business Wire | Press release

Share
GWI Revolutionizes Market Research With Brand-new Platform, Democratizing Access to Impactful Audience Insights

GWI, the leading target audience insight company, today launches its brand-new platform that challenges the status quo in market research. The multi-million dollar investment into the new platform provides access to transformational insights, in a meaningful and visual way. Arming employees with one, consistent in-depth view of their global or local audience, the new capabilities power strategic decisions and enable deep understanding of diverse and evolving audiences.

The new platform makes it easy to be an expert on your audience with smart tools that make it simple to explore available datasets. Users are now able to rapidly access deep insights, answering the questions that matter most to make key business decisions based on facts they can trust. It aids businesses to be truly data-driven by putting accessible insights and bespoke dashboards into the hands of everyone across the organization - from decision makers in the C-suite to data analysts, researchers and marketers.

Tom Smith, CEO and Founder at GWI comments, “The new platform enables a new dawn for the future of marketing research, ensuring it is suited for today's environment which consists of rapid change of pace for business and consumers. Our data shows that 72%* of professionals globally agree that being able to adapt quickly is critical to their company’s long term success. Yet, the traditional market research industry has utterly failed the needs of its customers in today's global marketplace - a world where almost 5 billion people are permanently connected online. Uncovering really transformative insight isn’t easy, nor is it always ‘on time’. Traditional research often takes several months, and can be delayed throughout the process. Despite heavy investment, the insights can therefore quickly become outdated, whilst putting market research out of reach for nearly every single organisation.

“With our new platform combined with our tried and tested methodology, you can secure insights and answers in an instant versus a drawn out process, at a fraction of the traditional market research cost. At the same time, you can ensure organizational alignment, meaning everyone is working from a single source of truth - to tell the same story, inform the decisions that matter and deliver impactful results.”

The intuitive new platform provides access to the world’s largest harmonized ongoing study on digital consumers, representing 2 billion people globally. Users of the flagship survey, GWI Core, alone can gather insights from over 40,000 data points, from over 800,000 interviews. The new platform will foster smarter business decisions and outcomes using hyper-targeted insights into any consumer group, in local and global markets.

To learn more about the new platform including new features and capabilities or to book a demo please visit here .

ENDS

About GWI

GWI is the leading supplier of target audience insight to the global marketing industry.

Trusted by the world’s biggest brands, media organizations, and agencies on a daily basis to get closer to their audiences, the company’s flagship survey represents over 2 billion people globally. Using the subscription-based platform, clients like Twitter, Google, Spotify, WPP, IPG, and Omnicom Group gather in-depth insights into behaviors, attitudes, and interests in seconds through a combination of survey data and analytics.

Among a range of leading data products available alongside its flagship survey are:

  • GWI USA is a deep dive into the habits, behaviors and attitudes of 240m internet users in the USA.
  • GWI Gaming delves into the actions and attitudes of gamers across 15 markets.
  • GWI Sports investigates sports fandom and participation across 15 markets.
  • GWI Kids gets to the heart of how kids actually think, so you can be sure to kid-proof your ideas and concepts from here on.
  • GWI Work gives a detailed view of the lives of business professionals across 10 markets.
  • GWI Zeitgeist, included with our core survey, is fielded monthly and zeroes in on the stuff that matters. It’s topical, timely, and relevant.

Those looking for even more bespoke research solutions can enrich GWI data with a range of services like hyper-targeted custom surveys, brand trackers, and recontact studies.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye